IndieBio
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Pre-Seed, Series A, Series B, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, Japan, China, India, Ireland, Taiwan
Industries Focus
- Healthcare
- Energy
- Education
- Agriculture
- FoodTech
- FinTech
- E-commerce
- SaaS
- Blockchain
- Life Sciences
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Sustainability
- Robotics
- Biotechnology
- Food & Beverage
- Pharmaceutical
- Life Science
- Regenerative Medicine
- Materials Science
- Environmental Services
- Computational Biology
- Therapeutics
- Clean Technology
- Adtech
- Biopharma
- Health Diagnostics
- Genetics
- AI/ML
- Neurotech
- Consumer Biology
- Industrial Biology
Investment Size:
150,000 to 500,000 USD
Investor Details Founded: 2014
IndieBio is a prominent accelerator program dedicated to nurturing early-stage life sciences startups. Operating under SOSV, a global venture capital firm, IndieBio provides comprehensive support to entrepreneurs aiming to address significant challenges in human and planetary health. The program offers initial investments ranging from $150,000 to $500,000, along with access to well-equipped facilities and a network of experts to help founders develop their products and launch their companies.
With locations in New York City and San Francisco, IndieBio has been instrumental in fostering innovation in biotechnology, healthcare, agriculture, and environmental services. The program's focus spans various sectors, including pharmaceuticals, medical devices, diagnostics, genetics, and clean technology. By offering resources and mentorship, IndieBio aims to accelerate the growth of startups that contribute to sustainability and address global health issues.
Since its inception, IndieBio has supported numerous startups, many of which have achieved significant milestones in their respective fields. The program's success is attributed to its rigorous selection process, extensive support system, and commitment to advancing breakthrough technologies. IndieBio continues to play a pivotal role in shaping the future of life sciences by empowering entrepreneurs to bring innovative solutions to market.
Requirements
- Innovative biotechnology solutions addressing human and planetary health challenges
- Early-stage life science companies seeking pre-seed or seed funding
- Founders committed to developing and scaling their innovations with comprehensive support
- Innovative biotech solutions addressing human and planetary health challenges
- Strong founding teams with diverse expertise
- Scalable business models with potential for significant impact
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Prellis Biologics
- Proteinea
- A2A Pharma
- Wayfinder Bio
- Minutia
- Prolific Machines
- CellCo
- OncoPrecision
- HexemBio
- BioSapien
- Ten63
- Frezent
- Cygenica
- Upside Foods
- MycoWorks
- Oobli
- Vertical Oceans
- Opentrons
- Flow Neuroscience
- TômTex
- Prellis
Mentioned In
-
$24.95
-
$24.95
-
$19.95
-
$49.95
-
$24.95
-
$14.95
-
$9.95
-
$19.95
-
$39.95
-
$99.00
-
$299.00
-
$95.00
Claim this Investor
Are you an official representative of IndieBio?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim